Arcutis Biotherapeutics (ARQT) to Post Earnings on Wednesday

Arcutis Biotherapeutics (NASDAQ:ARQT) is anticipated to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Arcutis Biotherapeutics to post earnings of $0.0551 per share and revenue of $118.8530 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.07). The business had revenue of $105.40 million for the quarter, compared to the consensus estimate of $103.67 million. Arcutis Biotherapeutics had a negative return on equity of 1.41% and a negative net margin of 0.57%. On average, analysts expect Arcutis Biotherapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Arcutis Biotherapeutics Price Performance

ARQT stock opened at $26.86 on Monday. Arcutis Biotherapeutics has a 1-year low of $13.69 and a 1-year high of $31.77. The business’s 50 day simple moving average is $25.55 and its 200 day simple moving average is $24.69. The company has a current ratio of 2.68, a quick ratio of 2.46 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $3.36 billion, a PE ratio of -895.03 and a beta of 1.48.

Insider Activity at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, Director Sue-Jean Lin sold 4,946 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.38, for a total value of $120,583.48. Following the transaction, the director directly owned 27,567 shares of the company’s stock, valued at $672,083.46. This represents a 15.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Howard G. Welgus sold 4,096 shares of Arcutis Biotherapeutics stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.41, for a total value of $99,983.36. Following the sale, the director directly owned 38,378 shares of the company’s stock, valued at $936,806.98. This represents a 9.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 10,334 shares of company stock valued at $250,697. 9.40% of the stock is currently owned by insiders.

Institutional Trading of Arcutis Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Global Retirement Partners LLC acquired a new position in shares of Arcutis Biotherapeutics during the 4th quarter worth approximately $35,000. NewEdge Advisors LLC raised its position in shares of Arcutis Biotherapeutics by 209.0% in the fourth quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock valued at $45,000 after buying an additional 1,045 shares in the last quarter. Truvestments Capital LLC raised its position in shares of Arcutis Biotherapeutics by 114.2% in the fourth quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock valued at $87,000 after buying an additional 1,606 shares in the last quarter. Cibc World Markets Corp bought a new stake in shares of Arcutis Biotherapeutics in the fourth quarter valued at approximately $211,000. Finally, Brooklyn Investment Group acquired a new stake in Arcutis Biotherapeutics during the fourth quarter worth approximately $239,000.

Wall Street Analysts Forecast Growth

ARQT has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Wednesday, June 24th. Wall Street Zen raised shares of Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $36.00 target price on shares of Arcutis Biotherapeutics in a research note on Thursday, May 7th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.00.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.